This document provides information about a MIHTP-ECHO training session on COVID-19 vaccines. It includes the agenda, presenters, and an overview of MIHTP and the ECHO model. The presentation by Dr. Allen McCutchan will discuss COVID epidemiology, vaccine mechanisms of action, effectiveness, safety, and duration of protection. It will also cover implications for people living with HIV and emerging variants. A presentation by Captain UO Adekanye will provide an update on Nigeria's COVID vaccine rollout and implications for people living with HIV. The session aims to inform participants and facilitate discussion on these topics.
Project ECHO (Extension for Community Health Outcomes)icornpresentations
Sanjeev Arora MD, Distinguished Professor of Medicine (Gastroenterology/Hepatology); Director of Project ECHO®
Department of Medicine, University of New Mexico Health Sciences Center
Project ECHO (Extension for Community Health Outcomes)icornpresentations
Sanjeev Arora MD, Distinguished Professor of Medicine (Gastroenterology/Hepatology); Director of Project ECHO®
Department of Medicine, University of New Mexico Health Sciences Center
@EARLI19 paper on Professional Learning in the health sector in developing countries by Koula Charitonos (Open University, UK) and Allison Littlejohn (University of Glasgow, UK)
Colorectal screening evidence & colonoscopy screening guidelines Health Evidence™
Health Evidence hosted a 90 minute webinar examining colorectal cancer screening: benefits and harms, effective screening methods, and screening guidelines.Click here for access to the audio recording for this webinar: https://www.youtube.com/watch?v=JqOV-KHCBq8
Donna Fitzpatrick-Lewis, MSW, Senior Research Coordinator at the McMaster Evidence Review and Synthesis Centre and Dr. Maria Bacchus, Associate Professor of Medicine, Faculty of Medicine University of Calgary, and member of the Canadian Task Force on Preventive Health Care led the session. Donna presented the findings of the Synthesis Centre’s latest review and Dr. Bacchus presented findings from the Task Force’s latest guidelines:
Fitzpatrick-Lewis, D., Usman, A., Warren, R., Kenny, M., Rice, M., Bayer, A., Ciliska, D., Sherifali, D., Raina, P. Screening for colorectal cancer. Ottawa: Canadian Task Force on Preventive Health Care; 2015. Available: http://canadiantaskforce.ca/files/crc-screeningfinal2.pdf
Bacchus, C. M., Dunfield, L., Gorber, S. C., Holmes, N. M., Birtwhistle, R., Dickinson, J. A., Lewin, G., Singh, H., Klarenbach, S., Mai, V., Tonelli, M. (2016). Recommendations on screening for colorectal cancer in primary care. Canadian Medical Association Journal, cmaj-151125.
Among men and women, colorectal cancer is the second and third most common cause of cancer related death, respectively. Colorectal cancer screening guidelines, developed by the Canadian Task Force on Preventive Health Care, are based on a systematic review synthesizing evidence on the benefits and harms of screening, and the characteristics of effective screening tests. The guidelines, developed from the review, outline screening recommendations for adults aged 50 and older who are asymptomatic and not at high risk for colorectal cancer. This webinar provided a high level overview of the systematic review that informed these recommendations, followed by an overview of the recent Canadian screening guidelines.
A protocol for the management of breast cancer developed by the multidisciplinary oncology team at University of Nigeria Teaching Hospital, fully adapted to our environment
Comparative Effectiveness of a Multifaceted Intervention to Improve Adherence to Annual Colorectal Cancer Screening in Community Health Centers (RCT)
Présentation de David W. Baker au colloque "Recherche interventionnelle contre le cancer : Réunir chercheurs, décideurs et acteurs de terrain » - 17 et 18 novembre 2014, BnF, Paris
Mr. Thomas J. Chapel - Measure that Make a Difference! WHY Measure and WHAT t...John Blue
Measure that Make a Difference! WHY Measure and WHAT to Measure! - Mr. Thomas J. Chapel, Chief Evaluation Officer, Centers for Disease Control and Prevention (CDC), from the 2015 NIAA Antibiotic Symposium - Stewardship: From Metrics to Management, November 3-5, 2015, Atlanta, Georgia, USA.
More presentations at http://swinecast.com/2015-niaa-symposium-antibiotics-stewardship-from-metrics-to-management
Gamification as a means to manage chronic diseaseEngagingPatients
UPMC is exploring ways to better engage patients through shared decision making and new approaches to encourage patients and their families to take control of their health. This presentation describes a pilot program UPMC has initiated to leverage gamification as a means to manage chronic heart failure.
Accessing Diabetes Education Through TelehealthTAOklahoma
M. Dianne Brown, MS, RDN, LD, CDE
OU Physicians Diabetes Life Clinic at the Harold Hamm Diabetes Center
Cynthia Scheideman-Miller, MHSA
Heartland Telehealth Resource Center
Oklahoma Telemedicine Conference 2014: Telehealth Transition
October 16, 2014
Katherine Promer Flores, MD (she/her)
Staff Physician
Division of Infectious Diseases and Global Public Health
Department of Medicine
University of California San Diego
Daniel Lee, MD
Clinical Professor of Medicine
Division of Infectious Diseases & Global Public Health
Department of Medicine
University of California, San Diego
More Related Content
Similar to Military International HIV Training Program (MIHTP) ECHO Rounds (April 27, 2021)
@EARLI19 paper on Professional Learning in the health sector in developing countries by Koula Charitonos (Open University, UK) and Allison Littlejohn (University of Glasgow, UK)
Colorectal screening evidence & colonoscopy screening guidelines Health Evidence™
Health Evidence hosted a 90 minute webinar examining colorectal cancer screening: benefits and harms, effective screening methods, and screening guidelines.Click here for access to the audio recording for this webinar: https://www.youtube.com/watch?v=JqOV-KHCBq8
Donna Fitzpatrick-Lewis, MSW, Senior Research Coordinator at the McMaster Evidence Review and Synthesis Centre and Dr. Maria Bacchus, Associate Professor of Medicine, Faculty of Medicine University of Calgary, and member of the Canadian Task Force on Preventive Health Care led the session. Donna presented the findings of the Synthesis Centre’s latest review and Dr. Bacchus presented findings from the Task Force’s latest guidelines:
Fitzpatrick-Lewis, D., Usman, A., Warren, R., Kenny, M., Rice, M., Bayer, A., Ciliska, D., Sherifali, D., Raina, P. Screening for colorectal cancer. Ottawa: Canadian Task Force on Preventive Health Care; 2015. Available: http://canadiantaskforce.ca/files/crc-screeningfinal2.pdf
Bacchus, C. M., Dunfield, L., Gorber, S. C., Holmes, N. M., Birtwhistle, R., Dickinson, J. A., Lewin, G., Singh, H., Klarenbach, S., Mai, V., Tonelli, M. (2016). Recommendations on screening for colorectal cancer in primary care. Canadian Medical Association Journal, cmaj-151125.
Among men and women, colorectal cancer is the second and third most common cause of cancer related death, respectively. Colorectal cancer screening guidelines, developed by the Canadian Task Force on Preventive Health Care, are based on a systematic review synthesizing evidence on the benefits and harms of screening, and the characteristics of effective screening tests. The guidelines, developed from the review, outline screening recommendations for adults aged 50 and older who are asymptomatic and not at high risk for colorectal cancer. This webinar provided a high level overview of the systematic review that informed these recommendations, followed by an overview of the recent Canadian screening guidelines.
A protocol for the management of breast cancer developed by the multidisciplinary oncology team at University of Nigeria Teaching Hospital, fully adapted to our environment
Comparative Effectiveness of a Multifaceted Intervention to Improve Adherence to Annual Colorectal Cancer Screening in Community Health Centers (RCT)
Présentation de David W. Baker au colloque "Recherche interventionnelle contre le cancer : Réunir chercheurs, décideurs et acteurs de terrain » - 17 et 18 novembre 2014, BnF, Paris
Mr. Thomas J. Chapel - Measure that Make a Difference! WHY Measure and WHAT t...John Blue
Measure that Make a Difference! WHY Measure and WHAT to Measure! - Mr. Thomas J. Chapel, Chief Evaluation Officer, Centers for Disease Control and Prevention (CDC), from the 2015 NIAA Antibiotic Symposium - Stewardship: From Metrics to Management, November 3-5, 2015, Atlanta, Georgia, USA.
More presentations at http://swinecast.com/2015-niaa-symposium-antibiotics-stewardship-from-metrics-to-management
Gamification as a means to manage chronic diseaseEngagingPatients
UPMC is exploring ways to better engage patients through shared decision making and new approaches to encourage patients and their families to take control of their health. This presentation describes a pilot program UPMC has initiated to leverage gamification as a means to manage chronic heart failure.
Accessing Diabetes Education Through TelehealthTAOklahoma
M. Dianne Brown, MS, RDN, LD, CDE
OU Physicians Diabetes Life Clinic at the Harold Hamm Diabetes Center
Cynthia Scheideman-Miller, MHSA
Heartland Telehealth Resource Center
Oklahoma Telemedicine Conference 2014: Telehealth Transition
October 16, 2014
Katherine Promer Flores, MD (she/her)
Staff Physician
Division of Infectious Diseases and Global Public Health
Department of Medicine
University of California San Diego
Daniel Lee, MD
Clinical Professor of Medicine
Division of Infectious Diseases & Global Public Health
Department of Medicine
University of California, San Diego
Leandro Mena, MD, MPH
Chair and Professor of Population Health Science
Department of Population Health Science
University of Mississippi Medical Center
Maile Young Karris, MD
Associate Professor
Co-Director San Diego Center for AIDS Research Clinical Investigations Core
Divisions of Infectious Diseases & Global Public Health and Geriatrics & Gerontology
Department of Medicine
University of California San Diego
Edward Cachay, MD, MAS
Professor of Medicine
Division of Infectious Diseases & Global Public Health
Department of Medicine
University of California, San Diego
Gabriel Wagner, MD
Associate Clinical Professor
Division of Infectious Diseases & Global Public Health
Department of Medicine
University of California, San Diego
Jocelyn Keehner, MD
Infectious Disease Fellow
Division of Infectious Diseases & Global Public Health
Department of Medicine
University of California, San Diego
Richard Garfein, PhD, MPH
Professor
Herbert Wertheim School of Public Health and Human Longevity Science
Adjunct Professor
Division of Infectious Disease and Global Public Health
Department of Medicine
University of California, San Diego
Laura Bamford, MD, MSCE
Associate Professor of Medicine
Medical Director, Owen Clinic
Division of Infectious Diseases and Global Public Health
Department of Medicine
University of California, San Diego
Davey Smith, MD, MAS
Professor of Medicine
Chief, Division of Infectious Diseases and Global Public Health
Co-Director, San Diego Center for AIDS Research (CFAR)
Department of Medicine
University of California, San Diego
Elliot Welford, MD
Infectious Diseases Fellow
Division of Infectious Diseases & Global Public Health
Department of Medicine
University of California, San Diego
Darcy Wooten, MD
Assistant Professor of Medicine
Associate Program Director, Infectious Diseases Fellowship
Division of Infectious Diseases & Global Public Health
Department of Medicine
University of California, San Diego
Amutha Rajagopal, MD
Associate Physician Diplomate
Division of Infectious Diseases & Global Public Health
Department of Medicine
University of California, San Diego
Winston Tilghman, MD
Medical Director, STD Controller
HIV, STD & Hepatitis Branch of Public Health Services
County of San Diego Health & Human Services Agency
More from UC San Diego AntiViral Research Center (20)
Title: Sense of Smell
Presenter: Dr. Faiza, Assistant Professor of Physiology
Qualifications:
MBBS (Best Graduate, AIMC Lahore)
FCPS Physiology
ICMT, CHPE, DHPE (STMU)
MPH (GC University, Faisalabad)
MBA (Virtual University of Pakistan)
Learning Objectives:
Describe the primary categories of smells and the concept of odor blindness.
Explain the structure and location of the olfactory membrane and mucosa, including the types and roles of cells involved in olfaction.
Describe the pathway and mechanisms of olfactory signal transmission from the olfactory receptors to the brain.
Illustrate the biochemical cascade triggered by odorant binding to olfactory receptors, including the role of G-proteins and second messengers in generating an action potential.
Identify different types of olfactory disorders such as anosmia, hyposmia, hyperosmia, and dysosmia, including their potential causes.
Key Topics:
Olfactory Genes:
3% of the human genome accounts for olfactory genes.
400 genes for odorant receptors.
Olfactory Membrane:
Located in the superior part of the nasal cavity.
Medially: Folds downward along the superior septum.
Laterally: Folds over the superior turbinate and upper surface of the middle turbinate.
Total surface area: 5-10 square centimeters.
Olfactory Mucosa:
Olfactory Cells: Bipolar nerve cells derived from the CNS (100 million), with 4-25 olfactory cilia per cell.
Sustentacular Cells: Produce mucus and maintain ionic and molecular environment.
Basal Cells: Replace worn-out olfactory cells with an average lifespan of 1-2 months.
Bowman’s Gland: Secretes mucus.
Stimulation of Olfactory Cells:
Odorant dissolves in mucus and attaches to receptors on olfactory cilia.
Involves a cascade effect through G-proteins and second messengers, leading to depolarization and action potential generation in the olfactory nerve.
Quality of a Good Odorant:
Small (3-20 Carbon atoms), volatile, water-soluble, and lipid-soluble.
Facilitated by odorant-binding proteins in mucus.
Membrane Potential and Action Potential:
Resting membrane potential: -55mV.
Action potential frequency in the olfactory nerve increases with odorant strength.
Adaptation Towards the Sense of Smell:
Rapid adaptation within the first second, with further slow adaptation.
Psychological adaptation greater than receptor adaptation, involving feedback inhibition from the central nervous system.
Primary Sensations of Smell:
Camphoraceous, Musky, Floral, Pepperminty, Ethereal, Pungent, Putrid.
Odor Detection Threshold:
Examples: Hydrogen sulfide (0.0005 ppm), Methyl-mercaptan (0.002 ppm).
Some toxic substances are odorless at lethal concentrations.
Characteristics of Smell:
Odor blindness for single substances due to lack of appropriate receptor protein.
Behavioral and emotional influences of smell.
Transmission of Olfactory Signals:
From olfactory cells to glomeruli in the olfactory bulb, involving lateral inhibition.
Primitive, less old, and new olfactory systems with different path
Lung Cancer: Artificial Intelligence, Synergetics, Complex System Analysis, S...Oleg Kshivets
RESULTS: Overall life span (LS) was 2252.1±1742.5 days and cumulative 5-year survival (5YS) reached 73.2%, 10 years – 64.8%, 20 years – 42.5%. 513 LCP lived more than 5 years (LS=3124.6±1525.6 days), 148 LCP – more than 10 years (LS=5054.4±1504.1 days).199 LCP died because of LC (LS=562.7±374.5 days). 5YS of LCP after bi/lobectomies was significantly superior in comparison with LCP after pneumonectomies (78.1% vs.63.7%, P=0.00001 by log-rank test). AT significantly improved 5YS (66.3% vs. 34.8%) (P=0.00000 by log-rank test) only for LCP with N1-2. Cox modeling displayed that 5YS of LCP significantly depended on: phase transition (PT) early-invasive LC in terms of synergetics, PT N0—N12, cell ratio factors (ratio between cancer cells- CC and blood cells subpopulations), G1-3, histology, glucose, AT, blood cell circuit, prothrombin index, heparin tolerance, recalcification time (P=0.000-0.038). Neural networks, genetic algorithm selection and bootstrap simulation revealed relationships between 5YS and PT early-invasive LC (rank=1), PT N0—N12 (rank=2), thrombocytes/CC (3), erythrocytes/CC (4), eosinophils/CC (5), healthy cells/CC (6), lymphocytes/CC (7), segmented neutrophils/CC (8), stick neutrophils/CC (9), monocytes/CC (10); leucocytes/CC (11). Correct prediction of 5YS was 100% by neural networks computing (area under ROC curve=1.0; error=0.0).
CONCLUSIONS: 5YS of LCP after radical procedures significantly depended on: 1) PT early-invasive cancer; 2) PT N0--N12; 3) cell ratio factors; 4) blood cell circuit; 5) biochemical factors; 6) hemostasis system; 7) AT; 8) LC characteristics; 9) LC cell dynamics; 10) surgery type: lobectomy/pneumonectomy; 11) anthropometric data. Optimal diagnosis and treatment strategies for LC are: 1) screening and early detection of LC; 2) availability of experienced thoracic surgeons because of complexity of radical procedures; 3) aggressive en block surgery and adequate lymph node dissection for completeness; 4) precise prediction; 5) adjuvant chemoimmunoradiotherapy for LCP with unfavorable prognosis.
Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists Saeid Safari
Preoperative Management of Patients on GLP-1 Receptor Agonists like Ozempic and Semiglutide
ASA GUIDELINE
NYSORA Guideline
2 Case Reports of Gastric Ultrasound
Knee anatomy and clinical tests 2024.pdfvimalpl1234
This includes all relevant anatomy and clinical tests compiled from standard textbooks, Campbell,netter etc..It is comprehensive and best suited for orthopaedicians and orthopaedic residents.
Couples presenting to the infertility clinic- Do they really have infertility...Sujoy Dasgupta
Dr Sujoy Dasgupta presented the study on "Couples presenting to the infertility clinic- Do they really have infertility? – The unexplored stories of non-consummation" in the 13th Congress of the Asia Pacific Initiative on Reproduction (ASPIRE 2024) at Manila on 24 May, 2024.
Title: Sense of Taste
Presenter: Dr. Faiza, Assistant Professor of Physiology
Qualifications:
MBBS (Best Graduate, AIMC Lahore)
FCPS Physiology
ICMT, CHPE, DHPE (STMU)
MPH (GC University, Faisalabad)
MBA (Virtual University of Pakistan)
Learning Objectives:
Describe the structure and function of taste buds.
Describe the relationship between the taste threshold and taste index of common substances.
Explain the chemical basis and signal transduction of taste perception for each type of primary taste sensation.
Recognize different abnormalities of taste perception and their causes.
Key Topics:
Significance of Taste Sensation:
Differentiation between pleasant and harmful food
Influence on behavior
Selection of food based on metabolic needs
Receptors of Taste:
Taste buds on the tongue
Influence of sense of smell, texture of food, and pain stimulation (e.g., by pepper)
Primary and Secondary Taste Sensations:
Primary taste sensations: Sweet, Sour, Salty, Bitter, Umami
Chemical basis and signal transduction mechanisms for each taste
Taste Threshold and Index:
Taste threshold values for Sweet (sucrose), Salty (NaCl), Sour (HCl), and Bitter (Quinine)
Taste index relationship: Inversely proportional to taste threshold
Taste Blindness:
Inability to taste certain substances, particularly thiourea compounds
Example: Phenylthiocarbamide
Structure and Function of Taste Buds:
Composition: Epithelial cells, Sustentacular/Supporting cells, Taste cells, Basal cells
Features: Taste pores, Taste hairs/microvilli, and Taste nerve fibers
Location of Taste Buds:
Found in papillae of the tongue (Fungiform, Circumvallate, Foliate)
Also present on the palate, tonsillar pillars, epiglottis, and proximal esophagus
Mechanism of Taste Stimulation:
Interaction of taste substances with receptors on microvilli
Signal transduction pathways for Umami, Sweet, Bitter, Sour, and Salty tastes
Taste Sensitivity and Adaptation:
Decrease in sensitivity with age
Rapid adaptation of taste sensation
Role of Saliva in Taste:
Dissolution of tastants to reach receptors
Washing away the stimulus
Taste Preferences and Aversions:
Mechanisms behind taste preference and aversion
Influence of receptors and neural pathways
Impact of Sensory Nerve Damage:
Degeneration of taste buds if the sensory nerve fiber is cut
Abnormalities of Taste Detection:
Conditions: Ageusia, Hypogeusia, Dysgeusia (parageusia)
Causes: Nerve damage, neurological disorders, infections, poor oral hygiene, adverse drug effects, deficiencies, aging, tobacco use, altered neurotransmitter levels
Neurotransmitters and Taste Threshold:
Effects of serotonin (5-HT) and norepinephrine (NE) on taste sensitivity
Supertasters:
25% of the population with heightened sensitivity to taste, especially bitterness
Increased number of fungiform papillae
263778731218 Abortion Clinic /Pills In Harare ,sisternakatoto
263778731218 Abortion Clinic /Pills In Harare ,ABORTION WOMEN’S CLINIC +27730423979 IN women clinic we believe that every woman should be able to make choices in her pregnancy. Our job is to provide compassionate care, safety,affordable and confidential services. That’s why we have won the trust from all generations of women all over the world. we use non surgical method(Abortion pills) to terminate…Dr.LISA +27730423979women Clinic is committed to providing the highest quality of obstetrical and gynecological care to women of all ages. Our dedicated staff aim to treat each patient and her health concerns with compassion and respect.Our dedicated group ABORTION WOMEN’S CLINIC +27730423979 IN women clinic we believe that every woman should be able to make choices in her pregnancy. Our job is to provide compassionate care, safety,affordable and confidential services. That’s why we have won the trust from all generations of women all over the world. we use non surgical method(Abortion pills) to terminate…Dr.LISA +27730423979women Clinic is committed to providing the highest quality of obstetrical and gynecological care to women of all ages. Our dedicated staff aim to treat each patient and her health concerns with compassion and respect.Our dedicated group of receptionists, nurses, and physicians have worked together as a teamof receptionists, nurses, and physicians have worked together as a team wwww.lisywomensclinic.co.za/
Explore natural remedies for syphilis treatment in Singapore. Discover alternative therapies, herbal remedies, and lifestyle changes that may complement conventional treatments. Learn about holistic approaches to managing syphilis symptoms and supporting overall health.
Prix Galien International 2024 Forum ProgramLevi Shapiro
June 20, 2024, Prix Galien International and Jerusalem Ethics Forum in ROME. Detailed agenda including panels:
- ADVANCES IN CARDIOLOGY: A NEW PARADIGM IS COMING
- WOMEN’S HEALTH: FERTILITY PRESERVATION
- WHAT’S NEW IN THE TREATMENT OF INFECTIOUS,
ONCOLOGICAL AND INFLAMMATORY SKIN DISEASES?
- ARTIFICIAL INTELLIGENCE AND ETHICS
- GENE THERAPY
- BEYOND BORDERS: GLOBAL INITIATIVES FOR DEMOCRATIZING LIFE SCIENCE TECHNOLOGIES AND PROMOTING ACCESS TO HEALTHCARE
- ETHICAL CHALLENGES IN LIFE SCIENCES
- Prix Galien International Awards Ceremony
These lecture slides, by Dr Sidra Arshad, offer a quick overview of physiological basis of a normal electrocardiogram.
Learning objectives:
1. Define an electrocardiogram (ECG) and electrocardiography
2. Describe how dipoles generated by the heart produce the waveforms of the ECG
3. Describe the components of a normal electrocardiogram of a typical bipolar leads (limb II)
4. Differentiate between intervals and segments
5. Enlist some common indications for obtaining an ECG
Study Resources:
1. Chapter 11, Guyton and Hall Textbook of Medical Physiology, 14th edition
2. Chapter 9, Human Physiology - From Cells to Systems, Lauralee Sherwood, 9th edition
3. Chapter 29, Ganong’s Review of Medical Physiology, 26th edition
4. Electrocardiogram, StatPearls - https://www.ncbi.nlm.nih.gov/books/NBK549803/
5. ECG in Medical Practice by ABM Abdullah, 4th edition
6. ECG Basics, http://www.nataliescasebook.com/tag/e-c-g-basics
Military International HIV Training Program (MIHTP) ECHO Rounds (April 27, 2021)
1. Cliquez ici et choisissez votre langue
1
Clique aqui para escolher o seu idioma
Click here to select your language.
Computers
Computadores / Ordinateurs
Cell Phones
Telemóveis/Téléphones mobiles
Passo 2
Passo 1
Instructions on how to select your language
Instruções sobre como selecionar o seu idioma / Instructions pour choisir votre langue
Passo 2
Passo 1
Welcome to MIHTP ECHO
Bem-vindos ao MIHTP ECHO / Bienvenue au MIHTP ECHO
Português
Français
Étape 1
Étape 2
Étape 1
Étape 2
2. Welcome
.
Department of Defense HIV/AIDS Prevention Program
Military International HIV Training Program (MIHTP)
MIHTP-ECHO Training
.
Attendance: Please confirm To confirm attendance please
enter your (1) first name, (2) last name, (3) email, (4) country
in one line in the chat.
.
This MIHTP-ECHO Session will begin shortly. 2
3. Department of Defense HIV/AIDS Prevention Program
Military International HIV Training Program (MIHTP)
ECHO Rounds (Module 10)
.
Tuesday, April 27, 2021
.
07:00-08:30 (San Diego, CA, USA, UTC -8)
15:00-16:30 Republic of the Congo, Brazzaville [WAT; UTC+0100]
16:00-17:30 South Africa, Johannesburg [SAST; UTC+0200]
17:00-18:30 Kenya, Nairobi [EAT; UTC+0300]
2:00pm-3:30 pm (Coordinated Universal Time, UTC) 3
4. English Presentation The slides presented today will be in English but
you may follow along with a translated version that was emailed
yesterday to the email address provided during registration.
.
Attendance via Zoom Registration
The Echo Zoom system has recorded your attendance upon
registration. If each person has not preregistered, a link will be
provided in the chat at the end of this session.
.
Attendance Confirmation
To confirm attendance please enter your (1) first name, (2) last name,
(3) email, (4) country in one line in the chat. 4
5. Recording
For educational and quality improvement purposes, we will
record this training session. By participating in this session you
are consenting to be recorded.
PHI Prohibited
Do not share Protected Health Information (PHI) or personally
identifiable information during this MIHTP-ECHO session.
Questions
If you have questions or comments, please email: Jorge Martins
at jmartins@gsshealth.com 5
6. Helpful Zoom Tips
- Mute microphone when not speaking
- Position webcam so other participants can see you
- You are welcome to have your camera on but if your audio is not
clear you may want to stop your video
.
Questions
Questions will be addressed in Q/A at the end each presentation.
You can use the chat function to submit questions or ask in Q/A.
.
We appreciate and value your participation.
6
7. Cliquez ici et choisissez votre langue
7
Clique aqui para escolher o seu idioma
Click here to select your language
Computers
Computadores / Ordinateurs
Cell Phones
Telemóveis/Téléphones mobiles
Passo 2
Passo 1
Instructions on how to select your language
Instruções sobre como selecionar o seu idioma / Instructions pour choisir votre langue
Passo 2
Passo 1
Welcome to MIHTP ECHO
Bem-vindos ao MIHTP ECHO / Bienvenue au MIHTP ECHO
Português
Français
Étape 1
Étape 2
Étape 1
Étape 2
8. AGENDA
Welcome / Administrative Announcements: Mike Grillo, Ph.D. 10 minutes
ECHO Overview
MIHTP Overview
Presentation: COVID-19 Vaccine Update: Implications for PLHIV & Significance of Evolving
Variants
Allen McCutchan M.D. MSc 35 minutes
Professor Emeritus Question and Answers 15 minutes
University of California, San Diego
..
Presentation: COVID-19 Vaccine Roll-out Update in Nigeria: Implications for PLWH
Captain UO Adekanye 10 minutes
Ministry of Defense Health Implementation Program-United States Army
Medical Research Directorate, Nigeria Q&A 5 minutes
.
General Discussion and Close 5 minutes 8
9. 9
MIHTP-ECHO Staff
• Dr. Mike Grillo – Facilitator
• Dr. Allen McCutchan - Presenter
• Dr. Edward (Lalo) Cachay – Presenter
• Jorge Martins– Interpreter / DHAPP ECHO Coordinator
• Rémi Charlebois – Interpreter
• Rachel Crane – Session Facilitator
• Lindsay Dapremont - Session Coordinator
• Mike Duszynski - Session Coordinator
• Karen Chow - Session Coordinator
10. ECHO Introduction
Project ECHO® [Extension for Community Healthcare Outcomes] is a model of
distance clinical mentorship developed at the University of New Mexico to
improve access to care for complex health problems for underserved
populations.
Elements of the model include:
• Hub-and-spoke networks
• Communities of Practice
• Didactics and case-based learning
• Chronic disease management
10
12. Improving Professional
Satisfaction/Retention
Supporting the Medical Home
Model
Cost Effective Care- Avoid Excessive
Testing and Travel
Prevent Cost of Untreated Disease
(e.g.: liver transplant or dialysis)
Integration of Public Health into
treatment paradigm
Potential Benefits of the ECHO Model
Quality and Safety
Rapid Learning and best-
practice dissemination
Reduce variations in care
Access for Rural and
Underserved Patients,
reduced disparities
Workforce Training and
Force Multiplier
Democratize Knowledge
12
13. § Mission
§ Provide flexible clinical training for clinicians in the prevention of HIV infection and
care and treatment for individuals with HIV infection receiving care through military
clinics and hospitals.
§ Objectives
§ Train medical personnel with the goal of transferring appropriate knowledge and
technology.
§ Promote HIV prevention programs through training of military medical providers
including prevention with positives programming.
§ Enhance the clinical skills of clinicians in the monitoring, evaluating, and follow-up of
patients with HIV infection. 13
14. § Collaboration of the Naval Medical Center San Diego (NMCSD), University of
California-San Diego (UCSD), and San Diego State University (SDSU).
§ Provide clinical training in HIV-related patient management, epidemiology, and
public health.
§ Emphasize understanding of military policies and
procedures regarding service members with HIV/AIDS.
A “train the trainer” method provides the
tools and educational materials to promote
current, up-to-date instructions to be taken
back to military medical community.
14
15. § DoD Policies and Procedures
§ DoD Instruction 6485.01
§ Army Regulation 600-110
§ Air Force Instruction 48-135
§ SECNAV 5300.30D/E Instruction
§ Discussion and support for developing
military HIV policies
§ Recruitment
§ Troop testing
§ Messaging for HIV negatives
§ Care and treatment programs for positives
15
16. § Behavior change
communication
§ Social marketing
§ Health Communication
§ SHARP & SHIP
§ Infection control for
health care workers
§ HIV Testing Services
§ Index Testing
16
17. § HIV clinical management training
§ Antiretroviral therapy, resistance, adherence
§ Opportunistic Infections, treatment and management
17
18. — Continuation of the program begins once trainees have arrived at home.
— Thank you and a “Next Steps” letter is emailed to all the participants.
— Keep in contact with DHAPP and your Desk Officer
— Start training others on the staff – (Call home anytime)
— Follow-up in the countries is ongoing through a variety of mechanisms
but mostly through close monitoring and discussions with DoD HQ staff.
— Follow-up evaluations have occurred showing increasing knowledge of our
attendees over time.
18
19. San Diego
MIHTP
(1 month)
Regional
MIHTP
(2 weeks)
Virtual
MIHTP-
ECHO
Total Attendees 288 126 644 +
attendees today
Physicians 255 - -
Nurses 7 - -
Auxiliary 26 - -
Total Courses 44 5 9
Total Countries 66 28 41 + new
countries today 19
20. — Angola
— Belize
— Benin
— Botswana
— Burkina Faso
— Burundi
— Cameroon
— Chad
— Colombia
— Cote d’Ivoire
— Comoros
— Djibouti
— Dominican Republic
— El Salvador
— Ethiopia
— Estonia
— Eswatini
— Gabon
— Georgia
— Ghana
— Guatemala
— Guinea Bissau
— Guinea Conakry
— Guyana
— Honduras
— Indonesia
— Jamaica
— Kazakhstan
— Kenya
— Kyrgyzstan
— Lesotho
— Liberia
— Madagascar
— Mali
— Malawi
— Montenegro
— Morocco
— Mozambique
— Namibia
— Nepal
•Nicaragua
•Niger
•Nigeria
• Papua New Guinea
• Peru
• Republic of South Africa
• Russia
• Rwanda
• São Tomé and Príncipe
• Senegal
• Serbia
• Sierra Leone
• South Sudan
• Swaziland
• Tajikistan
• Tanzania
• The Gambia
• Togo
• Uganda
• Ukraine
• United Arab Emirates
• Uzbekistan
• Vietnam
• Zambia
• Zimbabwe
20
Updated 3/31/2021
22. Allen McCutchan, MD, MSc, Professor
of Medicine, Emeritus (Active) in the
Division of Infectious Diseases,
Department of Internal Medicine,
University of California, San Diego.
• Associate Program Director of the
MAS in Clinical Research Program
• Co-Director UCSD Military
International HIV Training Program
• Co-Director, UCSD Training Program
in Clinical Research Methodology
22
..
Background
• Graduate of Yale School of Medicine
• Captain, Medical Core, US Army, with
service in US / Vietnam War
• Fellowship in Infectious Diseases, UCSD
• Masters in Epidemiology, London School
of Hygiene and Tropical Medicine, UK
• Founder & Director Emeritus, California
Collaborative HIV Treatment Group
• Author or coauthor of 320 peer-
reviewed research papers
23. COVID-19 Vaccine Update:
Implications for PLHIV &
Significance of Evolving Variants
Allen McCutchan, MD, MSc
Professor Emeritus
University of California, San Diego
Version 8 of 4-26-21
23
28. COVID Daily Incidence in 16 African Countries
(7-day average of cases/day up to 4/25/21)
Epidemic curves of
incident cases vary
among African
countries
- Steady increases in
Botswana
- Recent peaks in Togo
and Cameroon
- Multiple peaks of in
Ethiopia, Kenya and
RSA
28
32. SARS spike protein binding to human ACE2 Receptor
Site of binding of neutralizing antibodies
32
33. Neutralizing antibody to SARS COV2
• NA is generated by both COVID infection and by vaccines.
• Covid antibody is relatively easy to measure in serum, but
measuring functional antibody (NA) is more difficult than
antibody that simply binds to spike protein.
• Higher levels of NA correlate with protection from infection and
decreased severity of symptoms if infected.
• Levels after COVID disease and vaccination vary by several
logs among patients.
33
34. Levels of neutralizing antibody (NA) after COVID vary
greatly at 1.3 months and decline over 6 months
NA titer
(Log 10 of
Inhibitory
Concen-
tration
(IC50)
Baseline levels at 1.2 months vary by 1.7 logs and decline at 6.2 months
by an average of about one log (ie, by 10 fold or 90%)
Gaebler C, et al Nature 2021 591:639
104
101
34
36. Messenger RNA-based vaccines
m-RNA vaccine in
lipid nanoparticle
How m-RNA vaccine mechanism for
inducing immunity to COViD-19 spike
1) Nanoparticles containing m-RNA of spike
protein are injected and enter muscle
cells where they make spike protien
2) Antigen presenting cells activate B,
CD4+ and CD8+ T-lymphocytes to make
neutralizing antibody (NA) and cell
mediated immunity (CMI)
3) High levels of NA correlate with
protection in persons, but CMI may be
important to killing infected cells
NA
CMI
36
40. Assessing the effects of vaccines: issues
• Populations studied – In what type of population is the vaccine
being tested
• Efficacy – clinical trials in highly-selected volunteers for early
stages of research (phase I and II studies)
• Effectiveness - trials in persons who resemble those in the
community (phase 3 research studies and application in the public
health practice)
• What issues make make efficacy > effectiveness
• Greater adherence to taking medication (an issue only for two shot
vaccines) and to study visits
• More igorous adherence to conditions of storage such as low
temperature (very important for some COVID vaccines)
40
41. Assessing the effects of vaccines: issues
• Outcomes – What is counted as a success or a failure
• For persons before COVID infection
• Transmission of infection -> reduces risk of infection to others
• Reduction of illness severity -> prevention of severe illness and
death reduces burden on health care system (need for oxygen,
hospitalization, admission to IC), and management of the dead
by hospitals and funeral industry)
• For persons who have recovered from COVID infection
• Boosting of immunity to prevent reinfection
• Treatment of the long-lasting symptoms of post-COVID
illnesses (“long COVID” or “Post Acute COVID Sequela” =
PACS) - not yet well documented
41
42. Phase 3 study of effectiveness of Moderna vaccine
for preventing severe outcomes of COVID
93.0%
(CI 89-96)
80
5.6
Placebo - 80
Vaccine - 5.6
Incidence rate of COVID
cases / 1,000 pts)
Vaccine efficacy
Placebo
Vaccine
42
43. Comparison of efficacy among 8 COVID vaccines
Any
symptoms
Severe
disease
Neutralization of SARS COV2 variants
Britain Brazil South Africa
Vaccine
43
44. Moderna vaccine is less effective in older non-White patients,
but still very highly effective and appears to be similar by sex and race
Baden, LR et al Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine NEJM DOI:10.1056/NEJMoa2035389 44
45. Local adverse events: more
common than systemic AEs and
only pain was much more common
after both vaccine injections
Pain
Systemic adverse events all
increased more after the second
vaccine injection than the first
Rates of local and systemic adverse events after Moderna vaccine
Any reaction 45
46. Rates of anaphylactic reactions to m-RNA vaccines
21 = 0.000011 10 = 0.0000024
1.8 M 4.0 M
Pfizer Moderna
46
48. How can COVID vaccines control the
pandemic: Herd immunity
• Herd immunity (community or population immunity) is the
protection from an infectious disease when enough of a
population becomes immune through vaccination or previous
infection, to protect the rest of the population.
• Factors that increase herd immunity are the efficacy of the
vaccine and the percent of the population that is vaccinated.
• Herd immunity can be achieved by a combination of natural
COVID infections and vaccination even if the vaccine is not
100% effective.
• Epidemiological models of COVID suggest that vaccine efficacy
must be > 60% when coverage is 100%, and at least 80% when
coverage drops to 75%.
48
49. Who should be vaccinated against COVID first?
• Higher risk of exposure
• Medical: hospital personnel, ambulance drivers, undertakers,
and chronic elderly care staff and patients
• Essential workers: police and fire, food transport and sales,
public transportation, school teachers and staff, etc
• Residents in congregates settings: eg, military, prisons, schools,
• Higher risk for severe disease and death
• Older age
• Obesity (BMI > 30)
• Diabetes
• Chronic lung diseases (COPD, emphysema, or bronchitis)
• Immunosuppression (HIV, cancer, cancer hemotherapy, other
immunosuppressive drugs (rituximab)
49
50. What do we know about COVID in HIV-infected persons
§ COVID-19 infection rates may be increased because of social
conditions or poor access to health care rather than increased
susceptibility.
§ PWH with a high burden of comorbidities and low CD4 counts have
an increased risk of hospitalization.
.
§ PWH have worse clinical outcomes reflected by more frequent ICU
admission and mechanical ventilation.
§ PWH seem to have 30 to 50 % higher death rates from COVID-19.
§ Most PWH make good antibody responses to SARS-CoV-2, but low
CD4:CD8 ratio could compromise immune responses to acute COVID
or vaccines. 50
51. Main messages about COVID Vaccines in HIV
• An unknown number of HIV+ person were included in
vaccine clinical trials without obvious problems.
• Expert guidelines encourage giving HIV and other immune-
suppressed persons high priority for COVID vaccines.
• More specific data on safety and efficacy needs to be
developed.
51
52. Should people who have recovered from COVID be
vaccinated?
Yes, because: COVID infection induces immunity, but it is
not as strong as after vaccines and vaccines are safe after
COVID
§ Reinfection rates are reduced by 80-90% of that in those
without prior COVID, but this protection is not as good as
after the best vaccines (~94%)
§ Levels of neutralizing antibody are not as high as those after
vaccination and decline over the first 6 months.
§ Adverse reactions are not increased
§ COVID vaccine trials included persons regardless history
of COVID: for example 2.3% (n= 235) of Moderna vaccine
recipients in the phase 3 trial had antibody evidence of
prior COVID, and had decreased risk for adverse
reactions
52
53. COVID appears to induce substantial
immunity (resistance) to reinfection
• COVID reinfection rate was 11% over 6 months of follow-up
in British health care workers who had antibody evidence of
prior COVID compared to those without antibody.. Thus
reinfection was reduced by 89% and the cases tended to be
mild or asymptomatic.
• A similar study of US Marine recruits during the first 6 weeks
of their stressful and crowded basic training period of found
COVID reinfections were reduced by 84%
• Reinfection in the general Danish population was a) reduced
by 80%, b) similar for men and women and c) similar from
before to after 7 months of follow-up. 53
54. How will the genetic variants in SARS COV 2 affect
vaccine effectiveness: COVID transmission and
severity
54
55. Genetic variants of concern in SARS COV2
§ Three major variants that have rapidly become dominant within
their countries and regions of origin and are spreading
worldwide;
§ B.1.1.7 (Britain)
§ B.1.351 (South Africa)
§ B.1.1.28 also called P1 (Brazil)
§ All three variants have genetic mutations that change the amino
acids in the part of the spike protein that binds to the ACE-R on
human cells called the receptor binding domain.
§ These mutations have spread to many other countries and
threaten to spread faster and resist vaccines
55
56. Genetics of 3 Major SARS COV2 Variants
British variant B.1.1.7
Amino acids
N = asparagine
Y = tyrosine
E = glutamic acid
K = lysine
56
57. Effects of 3 genetic variants on aspects of SARS COV2
epidemiology and control by vaccines
• Greater transmissibility : All 3 variants have outcompeted and
replaced the original strains in their regions of origin. The British
variant appears about 50-70% more transmissible than its
ancestor
• Increased disease severity: The British variant (B.1.1.7) has
increased COVID mortality by 55-60% compared to its ancestor.
• Resistance to vaccine-induced immunity: The Astra-Zeneka
vaccine provided less protection from symptomatic infection in
phase 2 and 3 studies (70% for B.1.1.7 vs. 82% for non-B.1.1.7) 57
58. Spread of the British (B.1.1.7) variant
from UK to Europe from 12/2 to 3/21
Estimated increase in transmissibility of this variant is 50-70%
58
59. Comparison of NA induced by 5 of 8 COVID vaccines
Any
symptoms
Severe
disease
Neutralization of SARS COV2 variants
Britain Brazil South Africa
Vaccine
60. SARS COV2 variants and cell mediated immunity
• T-cell immunity to SARS COV-2 is directed at over 500 epitopes
(targets) on the entire virus, in contrast to neutralizing
antibodies which are directed to a small part of the viral spike.
• Of the three main SARS-CoV-2 variants from Britain, South
Africa, and Brazil, only a single amino acid change occurs
where T cells attach to activate cell mediated immune reactions.
• Since only one mutation could enable escape by modifying T
cell recognition, CD8+ T cells generated by an initial SARS-
CoV-2 infection should provide protection to people exposed to
any of the 3 variants.
• This prediction has not yet been proven in studies of patients.
60
61. Reasons that COVID variants may be controllable
• SARS COV2 mutates relatively slowly, so the generation of
variants depends on the large number of infected persons.
• If vaccines can control the pandemic in spite of current
variants, their generation of should decrease.
• Since rapid, universal, world-wide control of COVID by
vaccination is unlikely, variants will continue to appear and
may reverse protection from current vaccines.
• mRNA-based and other vaccines may be easily adjusted to
protect against new variants
• T-Cell mediated immunity (CMI) is important to control of many
viral infections and the current variants do not appear to have
increased resistance to CMI.
• CMI is difficult to measure and its role in control of SARS
COV2 is not well defined.
61
62. What are the social, economic, logistical and problems
of vaccinating the global population
§ Target is the world-wide human population which is:
• >7 billion persons.
• widely dispersed geographically,
• socio-economically, politically, and religiously diverse,
• mostly poor and under-educated (especially, in science)
§ Many people may be unwilling to be vaccinated (~40 in USA).
Vaccine hesitancy is more common in older, less educated, and
politically “conservative” men.
§ Vaccines are moderately expensive, require refrigeration and
sterile injection equipment and at least some medical skills
§ Animal reservoirs and genetic variation may undermine the long
term effectiveness of vaccines 62
63. COVID Denialism, Delusions and Vaccine Hesitancy
• COVID denialism is false beliefs that the pandemic is either:
• A hoax (lie) by the government designed to justify controlling the
population
• Not as serious or widespread as government and media portray it
• COVID delusions and conspiracy theories include these false beliefs:
• Scientists created/released COVID either intentionally or by accident
• Scientists and public health officials are exaggerating the seriousness of
the epidemic for political reasons or personal advantage
• Restrictions on travel, large indoor gatherings, requirements for masks
and distancing are unnecessary and illegal.
• Vaccine hesitancy includes these false beliefs that:
• Vaccines are undertested and therefore may be dangerous
• The injections might contain devices that can locate and track recipients
63
64. Reasons Africans give for vaccine hesitancy
Top 5 reasons for not taking
COVID vaccine
64
65. Dealing with COVID Denialism and Vaccine Hesitancy
• Communicating effectively with patients or groups
• Establish the reality and seriousness of the pandemic and be
positive about the protective effects of vaccines, masks,
distancing, and avoiding crowds (especially indoors, for
example at bars, restaurants or religious services where
singing and chanting aerosolizes SARS COV2
• Explain being vaccinated can both protect them and allow
them to visit safely with friends and family using the promise
of more relaxed restrictions:
• Level 1: All are vaccinated -> no restrictions
• Level 2: You, but not others are vaccinated -> masks and
distancing
• Level 3: No one is vaccinated -> All restrictions apply, ie,
masks, distancing, ventilate or meet outdoors if possible 65
66. Summary of vaccines and variants
• Safety and efficacy of COVID-19 vaccines have exceeded expectations
with high levels of protection from severe disease and lesser, but still
high, levels from infection
• Local and systemic side effects are common and short-lived and more
serious adverse reactions are very rare
• Remaining questions include vaccine efficacy in special populations
(HIV, children, malnourished, TB co-infected) and durability of the
vaccine immune response
• Fair and efficient vaccine distribution to all persons globally is an
ongoing challenge
• Vaccine hesitancy threatens adequate vaccine uptake, which is
necessary to control the COVID-19 pandemic
• SARS-CoV-2 variants are spreading rapidly and may effect
transmissibility, disease severity and vaccine efficacy
66
68. Captain UO Adekanye
Assistant Clinical Research Officer
Ministry Of Defense Health
Implementation Program
United States Army Medical
Research Directorate
68
69. COVID-19 Vaccine Roll-out
Update in Nigeria:
Implications for PLWH
BY
CAPT UO ADEKANYE
MINISTRY OF DEFENSE HEALTH IMPLEMENTATION PROGRAMME-
UNITED STATES ARMY MEDICAL RESEARCH DEIRECTORATE-
AFRICA/NIGERIA
69
70. BACKGROUND
• Over 164,233 confirmed COVID-19 cases
with 2,061 deaths as of 19 April 21
• HIV prevalence is 1.4%
• PLHIV ≈ 1.4 up to 10x mortality from
COVID-19*
• Ending the pandemic depends on global
vaccine coverage
*Osibogun A, Balogun M, Abayomi A, Idris J, Kuyinu Y, Odukoya O, et al. (2021) Outcomes of COVID-19 patients with comorbidities in
southwest Nigeria. PLoS ONE 16(3): e0248281. https://doi.org/10.1371/journal.pone.0248281 70
71. Technical Working
Group set up –
Nov 2020
Trainings and
vaccine arrival /
distribution
- Developed policy documents, guidelines, protocols,
training manuals
Trained ~6,500 Immunization managers and trainers at
National level and state level.
- Step downs to LGAs and vaccination teams
- First batch of ~4.925 million doses of vaccines received,
distribution plan and launching for 6th March. Accountability
framework and private sector engagement
- Launch of TEACH* strategy and Electronic Management
of Immunization Data (EMID)
- Electronic URL launched with 2.3 million electronic
registration within 24hours
*TEACH: Traditional Microplan, Electronic registration, Assisted registration and House to House e-registration
PRE-VACCINE ROLL-OUT ACTIVITIES
71
72. Vaccination rollout - target 37.85M eligible Nigerians
with 57.3M doses of COVID-19 vaccines
▪ 1: frontline
workers
▪ Some 60-
69 years
6.2m
doses
of AZ
• 2.8m eligible persons
• using Fixed post (60%) and
Temporary Fixed Post (40%)
• Campaign mode (~10days) in
rounds
Target Priority
Group
Phase 1
Phase 2
Vaccine
expected Population to be covered + Strategy
▪ 2&3: ≥50 –
59-70+, 18-
49 years
with Co-
morbidities
34.3m
doses
(AZ)
• 16.7m persons
• using FP (50%), TFP (30%), MT
(20%)
• Campaign mode (10days) in rounds
72
73. Vaccination rollout - target 38 M eligible Nigerians
with 57 M doses of COVID-19 vaccines
Phase 3
▪ Priority Group 4:
Focus on states /
LGAs with highest
burden and those
missing first 2 phases
18.4m
doses
(J&J)
• 18.4m persons
using FP (70%), TFP
(30%)
• Routine mode +
campaign
• 16.7m persons
• Vaccinated using FP (50%), TFP
(30%), MT (20%)
• Routine mode
Phase 4 ▪ Remainder of
eligible population
as vaccines become
available
Based on
available
vaccines*
• 70.2m persons
using FP (50%), TFP
(30%), MT (20%)
• Routine mode
73
74. COVID-19 Vaccine roll out and implications for PLHIV
Source: Daily Call-In Data
• HIV+ HCWs and PLHIV aged 60 – 69y in
phase 1
• Phase 2 for PLHIV aged 18 – 59y
• Phase 3 covers PLHIV missed in phase
1 and 2
• Phase 4 for remaining eligible persons
• Data limitation to monitor coverage in
PLHIV
74
77. UCSD:
Steven Wiersma, MD, MPH Michael P. Grillo, PhD, MS Michael Duszynski
Deputy Division Chief Director, MIHTP Program Manager
ECHO Coordinator Branch Chief Country Programs UCSD School of Medicine
steven.t.wiersma.civ@mail.mil Michael.p.grillo2.civ@mail.mil mduszynski@health.ucsd.edu
Lindsay Dapremont, MPH Jorge Martins Allen McCutchan, MD, MSc
MIHTP Coordinator DHAPP Professor of Medicine
Desk Officer ECHO Coordinator amccutchan@health.ucsd.edu
Lindsay.m.dapremont.ctr@mail.mil jmartins@gsshealth.com
Edward (Lalo) Cachay, MD, MS
Professor of Medicine
ecachay@health.ucsd.edu
Karen Chow
UCSD School of Medicine
kkchow@health.ucsd.edu 77
78. • A special thank you to Captain UO Adekanye for presenting today.
• If you have not done so yet, please confirm attendance by typing your
(1) first name, (2) last name , (3) email and (4) country in one line in
this chat box.)
• If you have not zoom registered, you can do so by using the link
provided in the chat.
• We appreciate your participation in a brief survey on this session that
will be emailed to you.
78